UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION
STATEMENT UNDER SECTION 14(d)(4) OF THE
SECURITIES EXCHANGE ACT OF 1934
Ocata Therapeutics, Inc.
(Name of Subject Company)
Ocata Therapeutics, Inc.
(Names of Persons Filing Statement)
COMMON STOCK, PAR VALUE $0.001 PER SHARE
(Title of Class of Securities)
67457L100
(CUSIP Number of Class of Securities)
Paul Wotton
President and Chief Executive Officer
33 Locke Drive
Marlborough, MA 01752
(Name, Address and Telephone Number, including area code, of Agent For Service)
With copies to:
Mitchell Bloom, Esq.
Andrew Goodman, Esq
William Collins, Esq.
Goodwin Procter LLP
Exchange Place
53 State Street
Boston, MA 02109
(617) 570-1000
(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of
the persons filing statement)
x Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
The information set forth under Items 1.01, 5.03, 7.01 and 9.01 of the Current Report on Form 8-K filed by Ocata Therapeutics, Inc. on November 10, 2015 (including all exhibits attached thereto) is incorporated herein by reference.